Search
for

    Glossary Everolimus

    medication that inhibits mTOR pathway, used in cancer treatment

    Everolimus is a medication that inhibits the mTOR (mammalian target of rapamycin) pathway, which is crucial for cell growth and proliferation. It is commonly used in cancer treatment to slow tumor growth and in organ transplantation to prevent rejection. Additionally, it has applications in treating certain rare diseases and conditions like tuberous sclerosis complex.

    Related Terms

    Learn

    2 / 801 results

      learn Rapamycin

      mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth

    Research

    5 / 113 results
      Cutaneous Toxicities From Transplantation-Related Medications

      research Cutaneous Toxicities From Transplantation-Related Medications

      14 citations , April 2017 in “American Journal of Transplantation”
      This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.

      research ТУБЕРОЗНЫЙ СКЛЕРОЗ (БУРНЕВИЛЛЯ-ПРИНГЛА). ОБЗОР ЛИТЕРАТУРЫ

      March 2026 in “Voprosy dermatologii i venerologii/Dermatologiâ ža̋ne veneralogiâ ma̋selelerì”
      This literature review highlights the critical importance of early dermatological diagnosis of tuberous sclerosis, focusing on its genetic basis, dermatological markers, and the role of genetic testing and multidisciplinary support, while discussing treatment options like mTOR inhibitors and their limitations.
      Virilizing Insulinoma

      research Virilizing insulinoma

      August 2025 in “Endokrynologia Polska”
      A rare pancreatic tumor caused a woman's male-like features, treated successfully with surgery and medication.

      research TRAPPED IN THE HYPOGLYCEMIA LOOP

      May 2025 in “Journal of the ASEAN Federation of Endocrine Societies”
      This case study highlights the aggressive progression and complex management challenges of metastatic insulinomas, with an emphasis on considering early systemic chemotherapy and advanced therapies like everolimus and PRRT for improved outcomes.